Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Satricabtagene autoleucel |
Synonyms | |
Therapy Description |
CT041 are autologous T-cells engineered to express a chimeric antigen receptor (CAR) targeting Claudin 18.2 (CLDN18.2), which may inhibit tumor growth (PMID: 30203099, PMID: 35534566). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Satricabtagene autoleucel | CT-041|CT 041|CT041|satri-cel | Satricabtagene autoleucel (CT041) are autologous T-cells engineered to express a chimeric antigen receptor (CAR) targeting Claudin 18.2 (CLDN18.2), which may inhibit tumor growth (PMID: 30203099, PMID: 35534566). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04404595 | Phase Ib/II | Satricabtagene autoleucel | Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers | Active, not recruiting | USA | CAN | 0 |